| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Collect Money & Be Organized, Whether you are running an event, fundraiser, or collecting money for another purpose, the tools you need to collect money online are right at your fingertips.
Pointwise is the choice for CFD (computational fluid dynamics) mesh generation, covering all of preprocessing from geometry model import to flow solver export.
Shortcuts is a company that provides salon and spa business management software in Australia and New Zealand. They work with over 15,000 businesses in 45 countries around the world, providing intuitive and easy-to-use software tailored to the unique ne...
A place where underrepresented communities are given realistic programming opportunities. We’re hiring. No degree required.